Predicting AIDS onset for individual patients.

Today’s physician may be confronted with a modern dilemma-the need to apply accumulating research information regarding markers predictiveof acquired iminunodeficiency syndrome (AIDS) to an individual patient who is infected with human immunodeficiency virus (HIV). Every physician would liketo have precise estimates ofrisk to guide the choiceoftherapy and to allow him or her to concentrateon the treatment ofthe patient and on the psychosocial complications of HW infection. Many studies have shown that AIDS risk is inversely related to CD4+ lymphocyte count (1-8). This fact partly justifies current recommendations to use prophylaxis with aerosolized pentamidine for Pneumocystis carinii pneumonia (9) in persons with CD4+ counts <200 ce!ls/L and to begin treatment with zidovudine (AZT) to reduce AIDS incidence in persons with counts <500 ce!ls/j.L (10-13). Following up early interest in serological markers (14-16), recent work has shown that AIDS risk for many (5, 6, 17-20) but not all (8) cohorts can be predicted more precisely by measuring not only CD4+ lymphocyte count but also the concentration of /32-microglobulin, neopterin, or interferon in serum. Improved risk models not only are helpful for managing individual patients, but also can be used to form homogeneous strata to increase the power of clinical trials. The work of Reibnegger et al. (21), reported in the March issue of Clinical Chemistry, not only showed that neopterin adds useful prognostic information to CD4+ counts but also presented a model that predicts absolute risk. Reibnegger et al. (21) reported the development of a statistical model for predicting individualized probabilities of developing AIDS over a 4.5-year follow-up period,based on initialCD4+ lymphocyte counts and neopterin concentrations in a cohort of 68 HIV-infected homosexual men. Their statistical model implies that the probability of disease in time interval t (t = 1,2,. 9, corresponding to successive half-year intervals), conditional on being at risk at the beginning of interval t, is

[1]  G Reibnegger,et al.  Individual probability for onset of full-blown disease in patients infected with human immunodeficiency virus type 1. , 1991, Clinical chemistry.

[2]  W. Guerra Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .

[3]  M. Desco,et al.  Immunological and serological markers predictive of progression to AIDS in a cohort of HIV‐infected drug users , 1990, AIDS.

[4]  P. Volberding,et al.  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. , 1990, The New England journal of medicine.

[5]  J. Goedert,et al.  Markers of risk in HIV-1. , 1990, The New England journal of medicine.

[6]  J. Montaner,et al.  Susceptibility to AIDS progression appears early in HIV infection , 1990, AIDS.

[7]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[8]  J. Goedert,et al.  Levels of CD4+ lymphocytes, neopterin and ß2-microglobulin are early predictors of AIDS , 1990 .

[9]  J. Goedert,et al.  Therapy may explain recent deficits in AIDS incidence. , 1990, Journal of acquired immune deficiency syndromes.

[10]  Recommendations for zidovudine: early infection. , 1990, JAMA.

[11]  G. Rutherford,et al.  Prevalence, incidence, and progression of human immunodeficiency virus infection in homosexual and bisexual men in hepatitis B vaccine trials, 1978-1988. , 1989, American journal of epidemiology.

[12]  J. Goedert,et al.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. , 1989, The New England journal of medicine.

[13]  J. Goedert,et al.  Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count. , 1989, Annals of internal medicine.

[14]  Peter Bacchetti,et al.  Incubation period of AIDS in San Francisco , 1989, Nature.

[15]  J J Goedert,et al.  Censoring in an epidemic with an application to hemophilia-associated AIDS. , 1989, Biometrics.

[16]  W. Blattner,et al.  Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. , 1989, Journal of acquired immune deficiency syndromes.

[17]  A. McBryde Acquired immunodeficiency syndrome (AIDS) , 2019, North Carolina medical journal.

[18]  R. Chaisson,et al.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort , 1988, British medical journal.

[19]  E. Werner,et al.  Neopterin as a marker in HIV infection. , 1988, Clinical chemistry.

[20]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[21]  J. Goedert,et al.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. , 1987, Annals of internal medicine.

[22]  J. Goedert,et al.  Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. , 1987, JAMA.

[23]  S. Zolla-Pazner,et al.  Quantitation of β2-Microglobulin and Other Immune Characteristics in a Prospective Study of Men at Risk for Acquired Immune Deficiency Syndrome , 1984 .

[24]  J. Goedert,et al.  Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. , 1983, The New England journal of medicine.

[25]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .